SGI-DNA Secures $25M in Series A Financing
Summary
The round was led by Northpond Ventures, with participation from Oxford Finance and BroadOak Capital Partners. The company intends to use the funds for the global commercial launch of its automated gene synthesis platform, further develop solutions that consolidate synthetic biology workflows, and expand its automated Gibson Assembly® applications, including an instrument that converts digitized DNA code to biological entities and a novel suite of DNA data storage solutions. Founded in 2014 and officially spun out of Synthetic Genomics, Inc. (SGI) in March of 2019, SGI-DNA develops synthetic genomics platforms that accelerate advances in drug discovery, precision medicine, DNA data storage and industrial design. In addition to the continuous commercial licensing of SGI-its Gibson Assembly intellectual property estate, comprising over 50 issued patents, the company will accelerate the development of innovative solutions, including the DBC System (Digital-to-Biological Converter) for on-demand printing of biological materials such as therapeutics and vaccines, and proprietary approaches to DNA synthesis and DNA data storage. SGI-DNA is led by Todd R. Nelson Ph.D., CEO, and Dan Gibson Ph.D., CTO.